<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01084408</url>
  </required_header>
  <id_info>
    <org_study_id>Pac 14</org_study_id>
    <nct_id>NCT01084408</nct_id>
  </id_info>
  <brief_title>Efficacy of the SeQuent®Please in the Treatment of De-novo Stenoses Versus Taxus™Liberté™</brief_title>
  <acronym>PEPCAD-DEBonly</acronym>
  <official_title>Randomized Trial on the Treatment of Coronary De-novo Lesions With a Drug Eluting Stent or a Drug Coated Balloon</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Saarland</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Saarland</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the trial is to assess the efficacy of the Paclitaxel-coated SeQuent®Please
      angioplasty balloon in the treatment of stenoses in native coronary arteries compared to a
      drug eluting stent.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>March 2010</start_date>
  <completion_date type="Anticipated">March 2020</completion_date>
  <primary_completion_date type="Anticipated">March 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Late lumen loss</measure>
    <time_frame>6 months</time_frame>
    <description>Late lumen loss = MLD in-lesion initially - MLD in lesion after six months (after nitroglycerin in identical projections); assessment by an independent Core Lab.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Thrombotic occlusion of the target lesion</measure>
    <time_frame>30 days, 6, 12, 24, 60 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Revascularization of the target lesion</measure>
    <time_frame>30 days, 6, 12, 24, 60 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Myocardial infarction</measure>
    <time_frame>30 days, 6, 12, 24, 60 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Death</measure>
    <time_frame>30 days, 6, 12, 24, 60 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Combined clinical endpoint (MACE)</measure>
    <time_frame>30 days, 6, 12, 24, 60 months</time_frame>
    <description>consisting of thrombotic occlusion of the treated segment, target lesion revascularization, myocardial infarction, or death</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Coronary De-novo Stenoses</condition>
  <arm_group>
    <arm_group_label>Sequent®Please</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Taxus™Liberté™</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>SeQuent®Please (Paclitaxel coated balloon)</intervention_name>
    <description>PCI of de-novo lesions</description>
    <arm_group_label>Sequent®Please</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Taxus™Liberté™ (Paclitaxel eluting stent)</intervention_name>
    <description>PCI of de-novo lesions</description>
    <arm_group_label>Taxus™Liberté™</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt; 18 years

          -  Clinical evidence of stable or unstable angina or a positive functional study

          -  Single, stenotic de novo lesion in a native coronary artery, type A or selected B1
             (see 4.3.1.1 Definition of lesion types)

          -  Diameter stenosis &gt; 70% (visual estimate)

          -  Vessel diameter 2.5 - 3.5 mm

          -  Female patients can enter this study if they are post-menopausal for at least two
             years or have undergone hysterectomy or sterilization

          -  Signed patient informed consent form

          -  Patient's and treating physician's agree that the patient will return for all required
             post procedure follow-up assessments as defined in the clinical protocol

        Exclusion Criteria:

          -  Left ventricular ejection fraction of &lt; 30%

          -  Visible thrombus proximal to the lesion

          -  Expection that treatment with devices other than PTCA will be required for this
             lesion.

          -  Stenosis is within a bypass graft

          -  Known hypersensitivity or contraindication to aspirin, heparin, clopidogrel,
             paclitaxel, or a sensitivity to contrast media which cannot be adequately
             pre-medicated

          -  Other medical illness (i.e. cancer, liver disease or congestive heart failure) that
             may require cytostatic or radiation therapy, cause the subject to be non-compliant
             with the protocol, confound the data interpretation or is associated with limited
             life-expectancy (i.e., less than two years).

          -  Acute myocardial infarction within the past 72 hours of the intended treatment
             (de-fined as: Q wave infarction having total creatinine kinase (CK) &gt;3 times the upper
             normal limit, or CK remains elevated above hospital normal at time of treatment)

          -  Chronic renal insufficiency with serum creatinine &gt; 2.0 mg%

          -  Significant gastrointestinal (GI) bleed within the past six months.

          -  History of bleeding diathesis or coagulopathy or will refuse blood transfusions

          -  Extensive peripheral vascular disease that precludes safe 6 French sheath insertion
             and / or requires additional anti-platelet and / or anti-coagulation treatment.

          -  Participating in another device or drug study within the last 6 months which may
             inter-fere with the interpretation of results of this study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bruno Scheller, Prof. Dr. med</last_name>
    <role>Principal Investigator</role>
    <affiliation>Uniklinikum des Saarlandes</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Klinik für Kardiologie, Angiologie und Konservative Intensivtherapie Klinikum Ernst von Bergmann</name>
      <address>
        <city>Postdam</city>
        <state>Brandenburg</state>
        <zip>14467</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinisches Versorgungszentrum</name>
      <address>
        <city>Hamburg</city>
        <zip>22527</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>May 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 9, 2010</study_first_submitted>
  <study_first_submitted_qc>March 9, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 10, 2010</study_first_posted>
  <last_update_submitted>May 11, 2016</last_update_submitted>
  <last_update_submitted_qc>May 11, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 12, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital, Saarland</investigator_affiliation>
    <investigator_full_name>Bruno Scheller</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>de-novo</keyword>
  <keyword>coronary stenoses</keyword>
  <keyword>PEPCAD</keyword>
  <keyword>DEBonly</keyword>
  <keyword>Paclitaxel</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Constriction, Pathologic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

